Novel Neurocognitive Testing Tool for Early Neurotoxicity Detection Following Anti-CD19 and Anti-BCMA Chimeric Antigen Receptor (CAR) T-cell Therapy: A Pilot Study
Brief neurocognitive testing can be feasibly applied for the early detection of ICANS after CAR T-cell therapy, predict which patients may go on to develop ICANS in the first 30 days, and overcome limitations of the ICE assessment tool.
Authors
- Maeen N Arslan
- Bryce S. Jacobson
- Amy Chan
- Grant G Moncrief (ORCID: https://orcid.org/0000-0001-5811-4308)
- Pablo Martínez‐Camblor (ORCID: https://orcid.org/0000-0001-7845-3905)
- Christi Ann Hayes
- Arvind Suresh (ORCID: https://orcid.org/0000-0002-6874-9734)
- Parth Shah (ORCID: https://orcid.org/0000-0003-2506-9525)
- Kenneth R. Meehan
- Heather A. Wishart
- John M. Hill
- Raphael A Lizcano
- Swaroopa PonnamReddy
Institutions
- Dartmouth College (US)
- Dartmouth–Hitchcock Medical Center (US)
- University of California, San Francisco (US)
Publication Details
- Journal
- Clinical Lymphoma Myeloma & Leukemia
- Published
- 2024-12-24
- DOI
- https://doi.org/10.1016/j.clml.2024.12.011
- Citations
- 4
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 1.13
Funders
- American Society of Hematology
- Dartmouth College
- Dartmouth Cancer Center